Aelis Farma Will Participate in the Addiction 2022 Conference Dedicated to Innovation in the Treatment of Addictions
22 September 2022 - 06:13PM
Business Wire
Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS,
PEA-PME eligible), a clinical-stage biopharmaceutical company
specialized in the development of treatments for brain diseases,
today announces its participation as a speaker at the Addiction
2022 international conference to be held from September 25 to 28,
2022 in Sardinia, Italy.
Pier Vincenzo Piazza, CEO of Aelis Farma, will give the
opening plenary lecture of the Addiction 2022 conference on
September 26, 2022. The title of the lecture is "Dangerous
Liaisons: How a general theory of addiction engendered a new class
of drugs". The presentation will focus on the discovery, mechanism
of action and effects of the new pharmacological class developed by
Aelis Farma, CB1-SSi, and more specifically on the first drug
candidate of this class, AEF0117, which targets disorders related
to excessive cannabis use (addiction and psychosis).
"That is an honor to be invited by the international scientific
community in the field of addiction to give this plenary lecture.
We are very proud to present our new pharmacological class,
CB1-SSi, and our most advanced drug candidate, AEF0117, to such a
prestigious group of scientists who are showing their interest in
the new class of drugs developed by Aelis Farma and more generally
in cannabis addiction. AEF0117 has shown indications of efficacy in
a phase 2a study and has entered a phase 2b study with a larger
population in the United States, a country particularly affected by
this type of addiction," said Pier Vincenzo Piazza.
***
About AELIS FARMA
Founded in 2013, Aelis Farma is a biopharmaceutical company that
is developing a new class of drugs, the Signaling Specific
inhibitors of the CB1 receptor of the endocannabinoid system
(CB1-SSi). These new molecular entities hold great potential in the
treatment of many brain diseases. CB1-SSi were developed by Aelis
Farma on the basis of the discovery of a new natural defense
mechanism of the brain made by the team of Dr. Pier Vincenzo
Piazza, CEO of the Company, when he was Director of the Inserm
Magendie Neurocenter in Bordeaux. For these discoveries, Dr. Piazza
was awarded the Inserm Grand Prix and the Grand Prix of Neurology
of the French Academy of Sciences, which are among the most
prestigious French prizes in medicine and neurology.
Aelis Farma is developing two first-in-class drug candidates
that are at the clinical stage, AEF0117 and AEF0217, and has a
portfolio of innovative CB1-SSi for the treatment of other diseases
associated with a dysregulation of the activity of the CB1
receptor.
AEF0117, which targets the disorders due to excessive cannabis
use (addiction and psychosis), has shown indications of efficacy in
a phase 2a clinical trial and has entered a phase 2b clinical trial
in the United States in the second quarter 2022. Aelis Farma has an
exclusive option-license agreement with Indivior PLC, a leading
pharmaceutical company in the treatment of addiction, for the
development and commercialization of AEF0117 for disorders due to
excessive cannabis use. As part of this agreement, Aelis Farma
received $30 million (option payment). If Indivior exercises the
license option at the end of the phase 2b, Aelis Farma will receive
a $100 million license fee (potentially in 2024) and up to $340
million in additional payments contingent on the achievement of
development, regulatory and commercial milestones as well as,
royalties on net sales of AEF0117 ranging between 12% and 20%.
AEF0217, which targets various cognitive disorders including
those associated with Down syndrome, has finished recruitments of
its phase 1 program in healthy volunteers and will start in the
fourth quarter 2022 a phase 1/2 study in Down syndrome subjects.
This compound has undergone an extensive preclinical
proof-of-concept program using highly innovative assessing
cognitive functions. In this context, AEF0217 has demonstrated its
ability to completely reverse cognitive deficits observed in
several animal models of neurodevelopmental disorders, such as Down
syndrome and Fragile X syndrome, as well as in models of certain
cognitive deficits associated with aging.
Based in Bordeaux, within the Magendie Neurocenter, Aelis Farma
has a team of 23 highly qualified employees and has benefited from
investments from the Nouvelle-Aquitaine Region, Inserm Transfert
Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and
IRDI Capital Investissement.
For more information: www.aelisfarma.com
ISIN: FR0014007ZB4 Ticker: AELIS B Compartment
of Euronext Paris
Disclaimer
Forward-looking statements
Some information contained in this press release are
forward-looking statements, not historical data. These
forward-looking statements are based on current beliefs,
expectations, and assumptions, including, but not limited to,
assumptions about Aelis Farma's current and future strategy and the
environment in which Aelis Farma operates. They involve known and
unknown risks, uncertainties, and other factors, which may cause
actual results, performance or achievements, or industry results or
other events, to differ materially from those described or implied
by such forward-looking statements. These risks and uncertainties
include those set out and detailed in Chapter 3 "Risk Factors" of
Aelis Farma's registration document approved by the Autorité des
marchés financiers on 14 January 2022 under number I.22-003.
These forward-looking statements are made only as of the date of
this press release and Aelis Farma expressly disclaims any
obligation or undertaking to release any updates or corrections to
the forward-looking statements included in this press release to
reflect any change in expectations or events, conditions or
circumstances on which any such forward-looking statement is based.
Forward-looking information and statements are not guarantees of
future performance and are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond Aelis Farma's control. Actual results could differ
materially from those described in, or implied or projected by,
forward-looking information and statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220922005780/en/
AELIS FARMA Pier Vincenzo Piazza CEO
contact@aelisfarma.com
NewCap Dusan Oresansky/Hugo Willefert Investor Relations
aelis@newcap.eu +33 1 44 71 94 92
NewCap Arthur Rouillé Relations médias aelis@newcap.eu
+33 1 44 71 00 15
Aelis Farma (EU:AELIS)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Aelis Farma (EU:AELIS)
Historical Stock Chart
Von Mär 2023 bis Mär 2024